1. What was the issue/problem identified?
Over the past two years, performance against the 62-day cancer standard has declined significantly in NHS Borders. In Q1 2025, the Board reported the lowest performance in Scotland at just 45.6%. The prostate cancer pathway was the main driver, accounting for 80% of all breaches, with pathway performance falling to only 12%. This was linked to rising referral numbers combined with capacity pressures across the wider Urology service.
2. What did you do?
We began by reviewing the diagnostic pathway and comparing local practice with that in other areas. This confirmed that the issues were a result of capacity rather than process. We then:
- Analysed referral numbers and conversion rates to confirm that the level of demand was appropriate.
- Carried out detailed breach analysis to identify which steps in the pathway were causing the most significant delays
3. What was the outcome?
Breach analysis showed that patients were breaching during the local diagnostic pathway, independent of delays for treatment at the regional centre. Principally, there were delays in the steps between MRI scan and prostate biopsy. These delays were a result of capacity issues, but capacity to make clinical decisions was also an issue.
To address this, we identified the need for additional administrative support and introduced a Pathway Navigator role. This enabled implementation of an ‘intentional’ pathway, where dates for next steps can be actively planned. For example, when a patient has a MRI scan, they are given an appointment to discuss results, based on when we know the scan will be reported. Further improvement is still required, including working with the regional team to try and refine the process for MDT decision making, but early results are promising and reported performance increased to 50% in July 2025, and provisionally to 70% in August 2025.
Contact
Steven Litster, Cancer Manager — steve.litster@borders.scot.nhs.uk